Roxadustat for Anemia in Patients with Kidney Disease Not Receiving Dialysis

2019555 citationsJournal Articlebronze Open Access

Authors

Nan Chen · Shanghai Jiao Tong University

Chuan‐Ming Hao · Fudan University

Xiaomei Peng · The People's Hospital of Guangxi Zhuang Autonomous Region

Hongli Lin · First Affiliated Hospital of Dalian Medical University

Aiping Yin · First Affiliated Hospital of Xi'an Jiaotong University

Hao Li · Second Hospital of Anhui Medical University

Ye Tao

Abstract

In Chinese patients with chronic kidney disease who were not undergoing dialysis, those in the roxadustat group had a higher mean hemoglobin level than those in the placebo group after 8 weeks. During the 18-week open-label phase of the trial, roxadustat was associated with continued efficacy. (Funded by FibroGen and FibroGen [China] Medical Technology Development; ClinicalTrials.gov number, NCT02652819.).

Topics & Keywords

Erythropoietin and Anemia Treatment Iron Metabolism and Disorders Dialysis and Renal Disease Management

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 381, Issue 11, pp. 1001-1010

DOI: 10.1056/nejmoa1813599

Field-Weighted Citation Impact: 54.58